BP
JAZZ icon

Banyan Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Banyan Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$557K Sell
3,472
-769
-18% -$118K 0.05% 290
2014
Q2 		$623K Buy
+4,241
New +$588K 0.05% 288

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Banyan Partners's JAZZ Position: Q3 2014 in Review

Banyan Partners reduced its Jazz Pharmaceuticals (JAZZ) stake by 18% in Q3 2014, selling an estimated $118K and leaving 3,472 shares worth $557K. The position accounts for 0.05% of the portfolio, ranked #290.

Banyan Partners first reported a position in JAZZ in Q2 2014 and has held it in 2 quarters since. The position peaked at $623K in Q2 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

  • Banyan Partners held 3,472 shares of Jazz Pharmaceuticals worth $557K as of Q3 2014.
  • Banyan Partners sold 769 Jazz Pharmaceuticals shares in Q3 2014, an estimated $118K.
  • Jazz Pharmaceuticals made up 0.05% of Banyan Partners's portfolio in Q3 2014, its #290 holding.
  • Banyan Partners first reported a position in Jazz Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • Banyan Partners's Jazz Pharmaceuticals position peaked at $623K in Q2 2014.
  • 325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on Banyan Partners's 13F filing for Q3 2014, filed 14 Nov 2014.